ASCO: Adding Olaparib Slows High-Risk Early Breast Cancer

FRIDAY, June 4, 2021 -- The addition of therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in an adjuvant setting improves invasive disease-free survival in early-stage human epidermal growth factor receptor 2 (HER2)-negative...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news